Oral minoxidil use in androgenetic alopecia and telogen effluvium.

Brittany Feaster, Toluwalashe Onamusi, Jerry E Cooley, Amy J McMichael

Other Archives of dermatological research 2023 16 atıf

<\/script>\n

`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'pmid\u003D35244759'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Study Design

Çalışma Türü: retrospective cohort
Örneklem Büyüklüğü: 210
Süre: 52 weeks

Müdahale: Oral minoxidil use in androgenetic alopecia and telogen effluvium. oral minoxidil 0.625–2.5 mg once daily
Karşılaştırıcı: Placebo
Etki Yönü: Positive
Yanlılık Riski: Moderate

Abstract

While current studies have supported oral minoxidil as a novel, adjunctive therapy in non-scarring forms of alopecia, there continues to be limited data on oral minoxidil for these conditions. To assess oral minoxidil use in the treatment of androgenetic alopecia and telogen effluvium, a multi-center, retrospective analysis was conducted in 105 adult patients treated for androgenetic alopecia and/or telogen effluvium with oral minoxidil (dose range 0.625-2.5 mg) once daily for ≥ 52 weeks, case matched by age (± 5 years) and gender with 105 controls with androgenetic alopecia and/or telogen effluvium who were not treated with oral minoxidil. 80 women (76.2%) with a mean age of 57.5 ± 13.56 (range 24-80) and 25 men (23.8%) with a mean age of 40.4 ± 13.79 (range 19-63) were included. Efficacy was evaluated based on provider assessment of clinical response and clinical photographic evaluation using a 3-point scale (worsening, stabilization, and improvement). 52.4% of patients demonstrated clinical improvement and 42.9% demonstrated stabilization. There was a significant difference in clinical response between the patient and control group, p < 0.001. Retrospective study design. These results suggest that oral minoxidil can be an effective treatment in androgenetic alopecia and telogen effluvium.